A new study on semaglutide was published on August 4, 2026. The publication appeared in Annals of Internal Medicine under the title "In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk."
The study focused on individuals with alcohol use disorder and comorbid obesity. It examined weekly semaglutide administration over a 26 week period. The reported title indicates a reduction in heavy drinking days at this timepoint.
This entry reflects the publication as indexed, including its title, journal, and date. No additional trial details, methodology, or outcome data beyond the title were provided in this record.
Semaglutide remains an approved compound, and this publication represents new literature regarding its use in the described population. Readers seeking background on approved indications and general information can consult the compound overview for further context.